Clavulanic Acid

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Cefpodoxime Proxetil and Potassium Clavulanate combines a third-generation cephalosporin with a beta-lactamase inhibitor. Clavulanic acid shields cefpodoxime from degradation by beta-lactamases produced by Staphylococcus aureus, H. influenzae, and enterobacteria. Indicated for community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute bacterial sinusitis, recurrent otitis media, and skin/soft tissue infections.

Cefixime and Potassium Clavulanate combines an oral third-generation cephalosporin with a potent beta-lactamase inhibitor. Clavulanic acid inactivates class A and other beta-lactamases, restoring and broadening cefixime's bactericidal potency against beta-lactamase-producing Haemophilus influenzae, Moraxella catarrhalis, E. coli, and Klebsiella pneumoniae. Indicated for refractory otitis media, acute bacterial sinusitis, community-acquired pneumonia, and complicated urinary tract infections.

Cefuroxime (as Cefuroxime Axetil for oral use or Cefuroxime Sodium for parenteral use) is a second-generation cephalosporin antibiotic. It resists degradation by many bacterial beta-lactamases and possesses bactericidal action against a broad spectrum of Gram-positive and Gram-negative organisms, including beta-lactamase-producing H. influenzae, Moraxella catarrhalis, S. pneumoniae, and S. aureus. Indicated for acute bacterial sinusitis, tonsillitis, acute otitis media, acute exacerbations of chronic bronchitis, uncomplicated UTIs, early Lyme disease, and surgical prophylaxis.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Cefixime and Potassium Clavulanate combines an oral third-generation cephalosporin with a potent beta-lactamase inhibitor. Clavulanic acid inactivates class A and other beta-lactamases, restoring and broadening cefixime's bactericidal potency against beta-lactamase-producing Haemophilus influenzae, Moraxella catarrhalis, E. coli, and Klebsiella pneumoniae. Indicated for refractory otitis media, acute bacterial sinusitis, community-acquired pneumonia, and complicated urinary tract infections.

Cefixime and Potassium Clavulanate combines an oral third-generation cephalosporin with a potent beta-lactamase inhibitor. Clavulanic acid inactivates class A and other beta-lactamases, restoring and broadening cefixime's bactericidal potency against beta-lactamase-producing Haemophilus influenzae, Moraxella catarrhalis, E. coli, and Klebsiella pneumoniae. Indicated for refractory otitis media, acute bacterial sinusitis, community-acquired pneumonia, and complicated urinary tract infections.

Faropenem and Potassium Clavulanate is an oral penem antibiotic combined with a beta-lactamase inhibitor. Faropenem exhibits high stability against many bacterial beta-lactamases and binds PBPs with high affinity to block bacterial cell wall synthesis; clavulanic acid broadens this spectrum against ESBL-producing organisms. Indicated for community-acquired respiratory tract infections (sinusitis, bronchitis, pneumonia), complicated urinary tract infections, and resistant skin infections.